Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) formats, becoming the country’s only company to offer the drug in all three biotechnology dosage forms: vials, pre-filled syringes, and pre-filled pens.
Semaglutide, a GLP-1 receptor agonist, is widely used for the management of Type 2 diabetes and is increasingly recognized for its role in weight and metabolic management.
The principal activity of the company is to manufacture and market pharmaceutical products.
Get the latest business news, market insights, and economic updates wherever you prefer.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.